Horizon Therapeutics plc is expanding its rare disease portfolio and pipeline with the acquisition of Viela Bio, Inc. for $3.05bn, looking to build on the success Horizon has experienced with the launch of Tepezza (teprotumumab) last year for thyroid eye disease. The acquisition of Viela will substantially bolster Horizon's portfolio, adding one commercial product, Uplizna (inebilizumab) for a rare autoimmune condition, and three pipeline products.
"This transaction represents a significant step forward in our transformation to an innovation-driven, high-growth biotech company," CEO Tim Walbert said...







